Another ETAR antagonist, zibotentan, significantly reduced albuminuria when combined with the SGLT2i dapagliflozin in a 12-week trial versus dapagliflozin alone in a study of 449 patients with various types of kidney disease (ZENITH-CKD) (17). The gene discussed is EDNRA; the disease is chronic kidney disease.